Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp. is a U.S.-based biotechnology company focused on discovering and developing therapies for central nervous system and other serious diseases. Its portfolio includes clinical-stage and discovery-stage programs, with operations conducted through a group of U.S., Australian, Portuguese, and former U.K. subsidiaries.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueTherapeutic candidates being advanced through clinical development and regulatory review.
Early-stage research programs aimed at identifying new drug candidates for CNS diseases.
Laboratory and translational work supporting target validation and candidate selection.
Internal functions supporting financing, IP, and advancement of the pipeline.
Customers
Pasithea does not appear to sell commercial products yet; its primary stakeholders are regulators, clinical investigators, and future healthcare customers that would use approved therapies. The eventual end customers would be patients and physicians in neurology and psychiatry, while near-term counterparties include research partners, capital providers, and clinical service providers supporting development.
Future users of PAS-003 if development succeeds; the program targets unmet need in amyotrophic lateral sclerosis.
Future users of PAS-001 if it advances successfully; the program is aimed at a major CNS indication.
Trial sites, investigators, CROs, and regulators that support preclinical and clinical advancement.
Equity, debt, and collaboration counterparties that fund development and extend operating runway.
Strategy
Pasithea’s strategy is to advance its pipeline through discovery, preclinical work, and clinical development while preserving access to external capital. The company also emphasizes maintaining intellectual property, building development capabilities, and preparing for eventual commercialization if any candidate is approved.
Pipeline progression is the main value driver for a pre-commercial biotech.
Development programs require funding before any product revenue exists.
IP underpins exclusivity and future partnering or commercialization value.
Geography
Pasithea is headquartered in the United States and operates through subsidiaries in the U.S. and Australia, with former entities in the U.K. and Portugal now discontinued. Its business is geographically shaped by where research, clinical development, and corporate financing activities can be conducted rather than by commercial sales markets.
Risks
Pasithea faces the typical risks of a pre-revenue biotech: clinical failure, regulatory delay, and the possibility that additional financing is unavailable or dilutive. It also has company-specific listing and capital-market risks, including Nasdaq bid-price compliance and restrictions tied to its public float.
- Financing shortfallImpact: CriticalLikelihood: Low
The company expects to need additional capital before it can fund development and operations.
Exposure - Pipeline development failureImpact: Critical
Drug candidates may not show sufficient safety or efficacy in preclinical or clinical testing.
Exposure - Nasdaq listing complianceImpact: HighLikelihood: High
Failure to maintain bid-price and other listing requirements could trigger delisting.
Exposure: Common stock and public warrants
- Competitive therapeutic landscapeImpact: Medium
Other approved or emerging therapies could limit market opportunity for its candidates.
Exposure: ALS and schizophrenia programs
Accounting
Judgemental itemsClinical and preclinical program costs are expensed as incurred and drive operating results.
Impact: Affects operating loss and cash burn
Equity awards are a common compensation tool in development-stage biotech companies.
Impact: Can materially increase reported expenses
Valuation of warrants or other instruments can create non-cash gains or losses.
Impact: Affects net income volatility
Liquidity depends on future financing and development milestones.
Impact: Important for solvency and disclosure analysis
Similar listed companies
Publicly listed companies with a comparable business focus.
Lisata Therapeutics, Inc
LSTA · Pharmaceutical Preparations
Lisata Therapeutics is a clinical-stage pharmaceutical company focused on developing certepetide, an investigational therapy designed to improve delivery of anti-cancer drugs into solid tumors.
Prothena Corporation plc
PRTA · Pharmaceutical Preparations
Prothena Corp.
MapLight Therapeutics, Inc.
MPLT · Pharmaceutical Preparations
Passage BIO, Inc.
PASG · Biological Products, (No Diagnostic Substances)
NuCana plc
NCNA · Pharmaceutical Preparations
NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer medicines based on its ProTide phosphoramidate chemistry platform.
Grace Therapeutics, Inc.
GRCE · Pharmaceutical Preparations
Last updated: 24/09/2026